# Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

> **NCT00695019** · PHASE2 · COMPLETED · sponsor: **Ainos, Inc. (f/k/a Amarillo Biosciences Inc.** · enrollment: 169 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** interferon-alpha lozenges
- **DRUG:** placebo lozenges

## Key facts

- **NCT ID:** NCT00695019
- **Lead sponsor:** Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-11
- **Final completion:** 2012-02
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695019, "Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00695019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*